Perspectives of pharmacological therapy of chronic obstructive pulmonary disease: opportunities of dual bronchodilation and a role of inhaled steroids. Expert Council Consensus

The most important symptoms of chronic obstructive pulmonary disease are dyspnea, cough and sputum production. According to results of several studies, 50% – 70% of COPD patients under regular therapy continue to experience dyspnea. Dyspnea has a great prognostic importance, it often correlates to exacerbation rate and the patients’ survival. Symptom reduction is one of the key outcomes of therapy of COPD. Measuring tools for assessment dyspnea are imperfect as dyspnea is a subjective feature. Nevertheless, available quantitative tools allow assessment symptom severity in COPD patients. Such tools (modified Medical Research Council scale and COPD Assessment Test – САТ) should be adopted to a medical care level (primary, secondary or tertiary care). Long-acting bronchodilators are the essential component of treatment COPD independently on COPD phenotype. COPD phenotype should be diagnosed before administration of combined drugs containing inhaled steroids (ICS). Long-term therapy with ICS is appropriate for the following groups of patients: overlap COPD and asthma phenotype; high risk of exacerbations (FEV1 < 50% pred., > 2 non-infectious exacerbations or > 1 hospitalization related to non-infectious exacerbation during the previous year); patients with sputum eosinophilia > 3% and / or blood eosinophilia > 300 cells × ml^-1 with consideration of the disease severity. A physician should consider a risk of adverse events of ICS. ICS should not be administered to COPD patients with FEV1 > 50% pred. or having < 2 acute exacerbations or no one hospitalization related to acute exacerbation of COPD during the previous year. ICS could be withdrawn if their administration did not match these criteria. Patients with persistent symptoms under monotherapy with long-acting bronchodilators, ICS / long-acting b2-agonists and who do not match the criteria for treatment with ICS should be treated with indacaterol / glycopyrronium combination.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2016. www.goldcopd.org/

2. Barnes P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 2014; 35: 71–86.

3. O'Donnell D.E., Mahler D.A. Effect of bronchodilators and inhaled corticosteroids on dyspnea in COPD. In: Mahler D.A., O'Donnell D.E., eds. Dyspnea: mechanisms, measurement and management. New York: Marcel Dekker; 2005: 283–299.

4. Miravitlles M., Worth H., Soler Catalu#ña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122.

5. Small M., Broomfield S., Pollard R., Fermer S. P208 impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities. Thorax. 2012; 67: A155.

6. Leidy N.K., Sexton C., Jones P.W. et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014; 69: 443–449.

7. van der Molen T., Willemse B.W., Schokker S. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcom. 2003; 1: 13.

8. Kon S., Canavan J., Jones S. et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir. Med. 2014; 2: 195–203.

9. Mahler D.A., Ward J., Waterman L.A. et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009; 136: 1473–1479.

10. Sutherland E.R., Cherniack R.M. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2689–2697.

11. Kessler R., Partridge M.R., Miravitlles M. et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur. Respir. J. 2011; 37: 264–272.

12. Hartman J.E., Boezen H.M., de Greef M.H.G. et al. Consequences of physical inactivity in chronic obstructive pulmonary disease. Exp. Rev. Respir. Med. 2010; 4: 735–745.

13. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

14. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1340.

15. Fletcher C.M., Elmes P.C., Wood C.H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br. Med. J. 1959; 1: 257–266.

16. Mahler D., Weinberg D., Wells C., Feinstein A. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest. 1984; 85: 751–758.

17. Oga T., Nishimura K., Tsukino M. et al. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir. Med. 2007; 101: 146–153.

18. Mahler D.A., Tomlinson D., Olmstead E.M. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61–65.

19. Cazzola M., Hanania N.A., MacNee W. A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges. Int. J. COPD. 2015; 10: 725–738.

20. Al-Ghabeesh S., Ahmad M. Unidimentional and multidimensional breathlessness specific instruments for adult population: Literature review. J. Nat. Sci. Res. 2012; 8: 1–15.

21. Pinto-Plata V.M., Cote C., Cabral H. et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur. Respir. J. 2004; 23: 28–33.

22. Cote C.G., Pinto-Plata V., Kasprzyk K. et al. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007; 132; 1778–1785.

23. Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochane Database Syst. Rev. 2012; 9: CD006829.

24. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332–338.

25. Gershon A.S., Campitelli M.A., Croxford R. et al. Combination long-acting #b-agonists and inhaled corticosteroids compared with long-acting #b-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014; 312: 1114–1121.

26. Yawn B., Kleerup E., Zhang J. et al. Inhaled corticosteroid use and GOLD severity stage among patients with chronic obstructive pulmonary disease in different regions [abstract]. Am. J. Respir. Crit. Care Med. 2012; 182: A2944.

27. Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.

28. Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22: 92–100.

29. Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45: 525–537.

30. Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 295–304.

31. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68: 1029–1036.

32. Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int. J. COPD. 2015; 10: 2535–2548.

33. Rossi A., Guerriero M., Corrado A. OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res. 2014; 15: 77.

34. Rossi A., van der Molen T., Olmo R. et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur. Respir. J. 2014; 44: 1548–1556.

35. Nadeem N.J., Taylor S.J., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD-a systematic review and comment on trial methodology. Respir. Res. 2011; 12: 107.

36. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371: 1285–1294.

37. Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179–191.

38. NICE. Clinical Guideline 101. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update issued June 2010). National Institute for Health and Clinical Excellence. Available from http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf

39. O'Reilly J., Jones M.M., Parnham J. et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. Br. Med. J. 2010; 340: 3134.

40. Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.

41. Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug. Des. Devel. Ther. 2013; 7: 1201–1208.

42. Rodrigo G.J., Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium (QVA149) for the treatment of COPD: a systematic review. Chest. 2014, 146: 309–317.

43. Bateman E.D., Mahler D.A., Vogelmeier C.F. et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Exp. Rev. Respir. Med. 2014, 8: 357–379.

44. European Medicine Agency. Ultibro Breezhaler. Available from EMA: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002679/human_med_001691.jsp (accessed October 15, 2014).

45. Health Canada. Available from Health Canada: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/regist/reg_innov_dr-end.pdf (accessed October 15, 2014).

46. U.S. Food and Drug Administration. Utibron Neohaler. Available from FDA: http://www.fda.gov

47. Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74: 465–488.

48. Dahl R., Chapman K.R., Rudolf M. et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 2013, 107: 1558–1567.

49. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013, 42: 1484–1494.

50. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013, 1: 199–209.

51. Banerji D., Fedele M.J., Chen H., Kim H.J. Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirology. 2013, 18 (Suppl. 4): 1–81.

52. Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013, 1: 51–60.

53. Zhong N., Wang C., Zhou X. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone combination (SFC) in patients with COPD: the LANTERN study. Eur. Respir. J. 2014; 44 (Suppl. 58): P2815.

54. Beeh K.-M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014, 108: 584–592.

55. Mahler D.A., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014, 43: 1599–1609.

56. Dahl R., Gallagher N., Green Y. et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD. Eur. Respir. J. 2013, 42 (Suppl. 57): 3385.

57. Dahl R., Jadayel D., Alagappan V.K. et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int. J. COPD. 2013, 8: 501–508.

58. Beeh K.M., Beier J. The short, the long and the «ultra-long»: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010; 27: 150–159.